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Abstract
Symptomatic oral Crohn's disease is comparatively rare. The relationship between orofacial
granulomatosis, (where there is granulomatous inflammation and ulceration of themouth in the
absence of gastrointestinal disease) and true oral Crohn's disease is discussed along with the
plethora of clinical oral disease presentations associated with both disorders and the
differential diagnosis of oral ulceration in patients presenting to a gastroenterological clinic.
Specific oral syndromes are outlined including the association between oral manifestations in
Crohn's disease and the pattern of intestinal disease and their relationship to other recorded
extraintestinal manifestations. The histological and immunological features of oral biopsies are
considered as well as the principles of management of symptomatic oral disease. At present, it is
suggested that both orofacial granulomatosis and oral Crohn's disease appear to be distinct
clinical disorders.
© 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.nt Surgery ‘B’, Department of
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Traditional teaching states that Crohn's disease is a disorder
affecting ‘the mouth to the anus,’ however, isolated Crohn's
disease of the upper gastrointestinal tract and especially oral
Crohn's disease (OCD) is a relatively uncommon finding where
understanding of its pathogenesis is evolving. In patients
with Crohn's disease who present with oral ulceration, before
a diagnosis of OCD is made, granulomas evident in biopsy
material need to be differentiated from other granulomatous
oral disorders including foreign-body reactions, sarcoidosis,
typical and atypical mycobacterial infection and fungal
sepsis.1–3 The term orofacial granulomatosis (OFG) was
coined by Wiesenfield et al. in 1995 to define the presence
of granulomatous oral ulceration without intestinal involve-
ment,4 although it is recognized that granulomatous mouth
ulcers may predate intestinal involvement in Crohn's
disease.5,6 The association between OFG and OCD currently
remains unclear where the risk factors for the progression of
OFG to ‘full-blown’ Crohn's disease are poorly understood. In
some cases, diagnostic confusion may occur where there is
an indeterminate colitis associated with aphthous oral
ulceration; a generally more common finding in patients
with ulcerative colitis.7 This article outlines the clinical
evaluation of the oral cavity, the pattern of oral lesions in
patients with known Crohn's disease and their known
association with other extraintestinal manifestations, dis-
cussing its clinical differentiation from patients with OFG.
The current views concerning the pathogenesis of both
conditions is discussed along with available data linking oral
ulceration to the likelihood of the development of intestinal
Crohn's disease. The difficulties in interpretation of the
incidence of oral lesions in Crohn's disease are analyzed with
a discussion of the management of symptomatic oral disease
in OCD and OFG patients.Table 1 Oral manifestations/pathologies associated with
Crohn's disease and orofacial granulomatosis.
Oral Crohn's Disease (OCD) Orofacial granulomatosis (OFG)
Periodontal disease and
caries
Lip swelling a
Aphthae/apthous
stomatitis
Facial swelling
Diffuse lip and buccal
mucosal swelling
Pyostomatitis vegetans
Oral cobblestoning Melkersson–Rosenthal syndrome
Buccal sulcus ulceration Frank ulcers (buccal with raised
edges, aphthae, microabscesses)Mucosal tags
Cheilitis
Labial and tongue fissuring
Glossitis
Palatal ulceration (rare)
a Disease confined to the lips is referred to as Meischer's
cheilitis granulomatosa.1.1. Clinical differentiation of oral Crohn's disease
(OCD) and orofacial granulomatosis (OFG)
There is a plethora of oral manifestations which have been
described in patients with Crohn's disease (Table 1). Many
oral lesions described in Crohn's disease are somewhat non-
specific, mimicking various forms of nutritional glossitis.8–10
The range of lesions in Crohn's disease includes diffuse lip and
buccal mucosal swelling, oral cobblestoning, buccal sulcus
ulceration and mucosal tags.11,12 Cobblestoning is usually
located on the posterior buccal mucosa and may be
associated with succulent mucosal folds with an intact
epithelium whereas mucosal tags are more commonly
found in the labial and buccal vestibules as well as in the
retromolar region. Many of these lesions may be preceded by
painless gingival enlargement13 and this finding in its earliest
stages should be distinguished from other known drug-
related, systemic and idiopathic causes of gingival hypertro-phy.14 These latter non-specific lesions, (unrelated to OCD),
show extensive deposition of collagen in the lamina propria
with over-expression on immunohistochemistry within the
pro-inflmmatory cellular infiltrates of matrix metalloprotei-
nases, most notably MMP-3 and TIMP-2,14 distinguishing them
from true OCD or OFG, both of which are unassociated with
these immunohistochemical changes. Ancillary oral lesions in
OCD include angular cheilitis, scaly perioral erythematous
rashes and frank intraoral abscess formation, although the
latter presentation is comparatively rare.15 Studies have also
shown in patients with inflammatory bowel disease, that
there is a higher prevalence of periodontal disease and caries
than noted in the normal population, where as many as 60%
of patients with Crohn's disease referred to dental units for
assessment show evidence of cheilitis, labial and tongue
fissuring, glossitis and aphthous stomatitis.16,17 Depending
on the clinical correlations and dedication towards oral
diagnosis in patients with Crohn's disease, oral lesions may be
identified in up to 60% of patients where in 5–10% of cases
they may be the first manifestation of disease.18
By contrast, OFG may present with discrete ulcers
although more commonly with lip and facial swelling as
well as distinct conditions including pyostomatitis vegetans
and the Melkersson–Rosenthal syndrome. The former condi-
tion manifests with soft pustular hyperplastic mucosal
folds19 although this has been reported uncommonly in
ulcerative colitis and very rarely in childhood Crohn's
disease.20 The histology in this condition is fairly specific
with localized eosinophilic infiltration within microabscesses
associated with pseudoepitheliomatous hyperplasia and
cellular acanthosis. These changes do not show IgA, IgG or
complement deposition, distinguishing it from pemphigus
vulgaris.21 The Melkersson–Rosenthal syndrome which is a
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swelling, facial paralysis and a fissured tongue, (so-called
lingua plicata) with lingual lesions most commonly located
on the lateral aspect of the dorsum of the tongue.22,23 In this
condition, facial palsy develops slowly only after other
clinical manifestations of OFG have already appeared.
Formes fruste of this disorder may include patients who
present only with isolated cheilitis (referred to as cheilitis
granulomatosa of Meischer)24 which is usually associated
with extensive orofacial swelling spreading to the chin, nose
and eyelids25,26 and which may be responsive to Infliximab
infusions in the absence of demonstrable gastrointestinal
disease.24,27
Currently, OCD and OFG are separated on clinical
grounds, where OFG tends to present with more labial
pathology and less oral ulceration. Labial enlargement
affects the upper and/or lower lips and is often persistentTable 2 Differential diagnosis in the clinic of granulomatous and no
clinic.
Diagnosis Extraoral findings
Granulomatous disorders
Oral Crohn's disease (OCD) Abdominal pain, diarrhea, rec
Orofacial granulomatosis (OFG) NIL
Foreign-body granuloma NIL/fever
Sarcoidosis Cough, fever, weight loss, ery
Oral tuberculosis Cough, haemoptysis, fever
Deep mycotic ulcer Candidiasis, Histoplasmosis
Paracoccidioidomycosis, Crypt
T cell lymphoma Fever, weight loss, lymphaedn
Wegener's granulomatosis Pulmonary, renal involvement
Oral syphilis Rash, genital ulceration
Cat-Scratch Disease Lymphaednopathy
ACE Angiotensin converting enzyme, IL-2 Interleukin-2, FTA Fluore
Haemagglutination assay; ANCA Anti-neutrophil cytoplasmic ant
Non-granulomatous disorders
Recurrent aphthous stomatitis
Nutritional deficiency
Oral malignancy
Coeliac disease Nausea, bloating, anemia, der
Herpetiformis
Behçet's syndrome Recurrent genital ulceration, u
Geographic tongue (benign
migratory glossitis)
HIV AIDS-related infection Weight loss, fever, lymphaden
Viral infection (Coxsackie, CMV,
EBV, HSV 1/2)
Sweet's syndrome a Fever, leukocytosis, skin papu
Vasculitis
Lichen planus
Pemphigus
CMV Cytomegalovirus, EBV Epstein–Barr virus, HSV Herpes simplex viru
ϕ Anti-transglutaminase and anti-endomysial antibodies.
KS Kaposi's sarcoma.
ELISA Enzyme linked immunosorbent assay.
a Fever, neutrophilia, recurrent oral ulceration associated with acutin nature rather than recurrent where the labial mucosa is
granular and erythematous in appearance but where
associated periroral midline and angular stomatitis tends to
be more scaly and exfoliative. If ulceration is present in
patients with OFG it takes one of 3 forms, including frank
deep buccal ulcers with raised peri-ulcerative mucosa,
aphthous-type ulcers or microabscesses which are usually
located on the gingival margin or on the soft palate.1.2. Histology of oral biopsies in OCD and OFG
The presence of granulomas on biopsy is the histological
hallmark of both OCD and OFG, where the differentiation
from other granulomatous oral disease is made on the
clinical picture accompanying the oral disease.3 Table 2
shows the differential diagnoses, diagnostic criteria andn-granulomatous oral ulceration detected in the gastrointestinal
Additional
diagnostic criteria
tal bleeding Gastroscopy, colonoscopy
\
thema nodosum Chest X ray, serum ACE,IL-2r
Z-N staining, Manotux, CD4 count,
bronchoscopy
ococcosis
Culture, CD4 count bronchoscopy
opathy T cell typing
ANCA antibodies
Treponemal antibody testing (FTA, TPHA)
Lymph node biopsy, anti-Bartonella
henselae antibodies
scent Treponemal antibody, TPHA Treponeme
ibodies
matitis Duodenoscopy
Serum antibody testing ϕ
veitis, arthritis Pathergy testing
opathy, KS lesions HIV ELISA, viral load assay, CD4 count
Anti-viral ELISA
les Associated AML
s.
e myeloid leukemia (AML).
Table 3 Histopathologic and histomorphologic differences
between OCD and OFG.
Pathologic features OCD OFG
Non-caseating granulomas + +
Loose macrophage clusters + −
Granulomatous lymphangitis + −
Fibrosis + +/−
Th-cell predominance Th1 Th2
T cell clonality within lesions − +
IgA antibodies to Saccharomyces cerivisiae + −
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patients presenting with biopsy-proven oral granuloma-
tous diseases as well as those presenting to the gastroin-
testinal clinic with persistent non-granulomatous oral
ulceration. The commonest cause of oral granulomas is a
foreign-body reaction usually as a response to a range of
dental materials including retained impressions and
amalgams as well as endodontic sealers28 where this
type of reaction more commonly presents as a mass rather
than frank ulceration and is accompanied by typical
foreign-body type giant cells surrounding foreign material
on biopsy. Specific infectious conditions leading to
granulomas include tuberculosis which is more often
seen as deep ulcerative oral disease particularly in
immunosuppressed patients where Ziehl–Neelsen staining
shows typical acid-fast bacilli and where granulomas are
caseating with an accumulation of Langhans-type giant
cells.29 Rarely fungal infections may be detected partic-
ularly occurring in Histoplasmosis, Cryptococcosis and
Pacoccidiodomycosis.30,31 Oral sarcoidosis is comparative-
ly rare, usually being associated with systemic symptoms
(fever, arthralgia, generalized lymphadenopathy and
weight loss) as well as hilar lymphadenopathy and where
the oral manifestations are typically multinodular with
associated salivary gland enlargement.32 Differentiation
can be made by labial gland biopsy33 and by serum
angiotensin converting enzyme, IL-2receptor and IL-
8 levels each of which correlates with disease activity.34
In OCD, there is a high reported rate of granulomata
(between 75 and 100%) found in oral biopsies of discrete
lesions, regardless of their form of presentation,12,18,35–37
although there is a spectrum between the presence of
discrete non-caseating granulomas through confluent gran-
ulomatous sheets of macrophages and multi-nucleate giant
cells to loose granulomatous macrophage clusters. This may
be accompanied by granulomatous lymphangitis and very
commonly by marked fibrosis. In biopsy material, differen-
tial lymphocyte accumulation discriminates between OCD
and OFG. In OCD, Th1 CD4+ lymphocytes are a hallmark37,38
with an association with NOD2/CARD 15 mutational
dysregulation on chromosome 16, particularly in those
with associated ileal disease.39,40 Mutations in this gene
predispose towards granuloma formation possibly as a
result of alterations in the innate immune response to
bacterial flora where CARD 15 encodes for intracellular
receptors for bacterial translocation.39 This genetic finding
has been linked to the detection of serum IgA antibodies to
Saccharomyces cerevisiae in patients who have OCD as a
further distinguishing factor separating it from cases of
OFG.41
In OFG there is a postulated overstimulation of the Th2
CD4+ leucocyte pathway with evidence of a locally restricted
T-cell receptor gene expression in the infiltrating lympho-
cytes derived from biopsies of lesions when compared with
those obtained from normal oral mucosa. This is suggestive of
a specific antigen-driven T cell clonal expansion42,43 al-
though the nature of the antigenic challenge in these
patients has yet to be identified. This is coupled with a
greater trend in patients with OFG to have coincident atopic
disorders as part of a Th2 CD4+ overstimulation where a
range of food hypersensitivities have been identified
(particularly to cinnamaldehyde and benzoate additives).44Currently, there is no available evidence that standard or
urticarial skin patch testing for patients with this type of OFG
presentation is, however, beneficial.45,46 Table 3 shows the
histopathologic differences between OCD and OFG when a
granulomatous oral biopsy is obtained.
1.3. Intestinal patterns of Crohn's disease
presenting with oral pathology
There is no clear or expected pattern of gastrointestinal
Crohn's disease presenting with oral manifestations.47
Whereas it would be anticipated that upper gastrointestinal
disease should be more common in such patients, there is
little prospective data to support this view.36,47 In this
respect, Dupuy et al. have reported a greater male
predominance, a young age of onset and a higher prevalence
of upper gastrointestinal involvement in patients who
present with oral manifestations in Crohn's disease where
patients tend to have a more protracted clinical course.48
Equally, Harty and colleagues have noted a higher incidence
of concomitant perianal Crohn's disease in those patients also
presenting with oral disease although their series numbers
were small.36 The natural history of oral disease associated
with active Crohn's disease is presently somewhat unclear,
where up to one-third of patients will continue to harbor oral
manifestations during follow-up.49 There is no significant
difference regarding intestinal location or disease activity
between patient subgroups which either cease or which
continue to harbor OCD, implying a diagnostic advantage in
oral examination only at the time of initial presentation.
Children who harbor oral disease generally display a more
significant disease burden, (a more severe Crohn's pheno-
type), corroborating the finding of the European Collabora-
tive Study on Inflammatory Bowel Disease that the presence
of upper gastrointestinal disease is a predictor of more
severe disease activity overall.50
There is considerable debate concerning whether oral
disease in patients with intestinal Crohn's disease should be
considered as an extraintestinal manifestation or whether it
is a reflection of overall mucosal disease activity. Despite the
fact that oral disease may predate intestinal involve-
ment,5,6,51 it is often not included as a specific extraintest-
inal manifestations of Crohn's disease, where Monsén et al. in
a Swedish epidemiology study excluded arthralgia, stomati-
tis and episcleritis in their clinical listing of extraintestinal
manifestations.52 Notably, aphthous stomatitis has some
degree of clinical linkage with peripheral arthritis, ankylos-
ing spondylitis, uveitis and erythema nodosum.53 The
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inflammatory bowel disease is a complex issue where if
major extraintestinal disorders are counted, the prevalence
is as high as 20–25%,54 however, if all potential systemic
effects and complications of therapy are included, almost all
patients will be listed as having some form of an extra-
intestinal manifestation. Whereas previously it has been
reported that extraintestinal manifestations are commoner
in those patients presenting with colonic Crohn's disease,55
the intestinal location and pattern of Crohn's disease has not
been found to be a significant factor on logistic regression for
any specific extraintestinal presentation.56 Moreover, in the
pediatric population, it is suggested that the incidence of
extraintestinal manifestations is significantly under-
reported, where aphthous stomatitis (which occurs overall
in about 8% of patients with inflammatory bowel disease), is
about 3 times more common in patients with Crohn's disease
than it is in ulcerative colitis.
The appearance of other non-oral extraintestinal man-
ifestations shows a stronger association with disease
activity at the time of diagnosis in both Crohn's and
ulcerative colitis, suggestive of a common pathogenetic
pathway between the development of the extraintestinal
and the inflammatory intestinal disease57,58 where the
appearance of one extraintestinal manifestation increases
the risk of development of another. Multiple extraintestinal
manifestations are, however, uncommon occurring in only
4.5% of cases and are more common in patients with Crohn's
disease.53 Difficulties with interpretation of this data
include the under-diagnosis of relevant associated extra-
intestinal manifestations in some cases, the variability in
the utilization of the term and the assessment of patient
cohorts in cross-sectional studies where only a few patients
will suffer from specific extraintestinal disorders at any one
time. Variability in their reported incidence also reflects
differences between prospectively and retrospectively
collected series,55 geographic variations in their inci-
dence59,60 and community variability in the recognition of
general non-inflammatory bowel disease-related aphthous
stomatitis, which itself is affected by gender, age and
smoking status.61,62 Registration of a condition as an
extraintestinal manifestation may not include disorders
which are an accompaniment to inflammatory bowel
disease and which run a course often independent of
disease activity or progression or which display an inherent
autoimmune element, such as thyroiditis, haemolytic
anemia or vitiligo. Further, inclusion of metabolically-
associated problems consequent upon enteric disease such
as nephrolithiasis, cholelithiasis and amyloidosis, may also
not be registered as extraintestinal manifestations in many
cases resulting in variable incidence reporting in the
literature.
By contrast, although OFG is defined as granulomatous oral
ulceration in the absence of clinical intestinal disease, half the
patients will have inflammatory changes on ileo-colonoscopy in
the absence of specific gastrointestinal symptoms, with two-
thirds of such cases showing granulomata on gut biopsy.63–65
Subclinical intestinal histological abnormalities are more likely
to be found (if investigated)where there is an early age of onset
of what is labeled initially as OFG or if there is more severe oral
inflammation detected either on clinical examination or noted
on oral mucosal biopsy.661.4. Management principles of OCD and OFG
Oral lesions in Crohn's disease may be asymptomatic and
some may spontaneously resolve over time. The range of
therapeutic options used in clinical decision-making for both
OCD and OFG patients is shown as a management algorithm in
Fig. 1, where severe labial and facial pathology requires
more aggressive systemic therapy. Pediatric patients with
OFG who also have coincident atrophy may often respond to
dietary restriction of potential triggering agents including
cinnamaldehyde, benzoate additives, carnosine, monoso-
dium glutamate, cocoa and sunset yellow, although there are
no available trial data beyond case reports concerning their
dietary exclusion.44,67,68 In symptomatic cases, treatment
can often be simple and non-specific with analgesia and
topical therapies, Beclomethasone mouth washes and 5-ASA
ointments or sprays.69 The range of treatments normally
available for symptomatic Crohn's disease may also be used
in those with very symptomatic OCD as well as part of a
progressive treatment program in patients with OFG,
particularly where there is oral disfigurement by fibrosing
granulomatous disease or where painful recalcitrant ulcer-
ation is unresponsive to basic therapies.
Alternatives in the treatment of deep painful ulcers
include the use of slow-release, highly concentrated
intralesional steroid therapy with or without mandibular
nerve blockade.70 In unresponsive cases, topical tacrolimus
at low concentration (0.5 mg/kg) is recommended where it
has also been reported to be successful in severe lip swelling,
resulting in minimal tachyphylaxis and systemic absorption,
although there is reported rebound symptomatology after its
cessation.71,72 Systemic steroids are of value in resistant
cases although when used alone they have been reported as
providing remission in only half the patients with only a
limited effect on lip swelling.73 Their long-term use is
contraindicated in children because of the risk of growth
retardation and in unresponsive patients where steroid
sparing is required, biologic therapies have been used with
success, including Infliximab,74,75 and Thalidomide76 with or
without the addition of methotrexate77 and other steroid-
sparing agents with anti-granulomatous properties including
the anti-leprosy drug clofazimine.781.5. Summary
The definition of OFG is conventionally used to describe
patients who present with granulomatous inflammation of the
oral cavity without overt clinical evidence of intestinal
inflammation. Its global incidence is rising partly because of
an increased awareness of the diagnosis particularly in the
pediatric population. At the same time, the incidenceofCrohn's
disease in high prevalence areas such as Northern Europe and
the United states is falling explaining the paradoxical increase
in OFG diagnosis.27,79 Granulomatous oral ulceration is a
specific biopsy finding with defined differential diagnoses
where the clinical separation of OFGandOCD is important since
the natural history of these conditions varies along with their
presumed aetiopathogenesis.
Although many patients presenting with oral lesions in such
circumstances are managed by dermatological and dental
experts, both gastroenterologists and coloproctologistsworking
Figure 1 Management algorithm for patients with both OFG and OCD presenting with granulomatous oral ulceration.
140 A.P. Zbar et al.in multidisciplinary inflammatory bowel disease clinics must be
clinically familiar with the range of disorders which constitute
the differential diagnosis once granulomatous oral disease has
been confirmed.3,80 Frequently oral disease is subclinical and
self-resolving, where specific disease patterns appear to
distinguish OFG from true OCD and where biopsy is only
diagnostic if taken into consideration with the overall clinical
picture. Oral disease in Crohn's is frequently not considered
specifically as an extraintestinal maninfestation and is often
inadequately documented so that its association with the
prospective development of intestinal disease is relatively
poorly understood. Depending on the dedication towards
diagnosis and oral examination, the incidence of demonstrable
oral pathology in patients with Crohn's disease can be relatively
high with the clinical pattern currently providing a relatively
clear separation from patients presenting with OFG.8,64,81,82 It
is recommended that there should be expert evaluation of the
oral cavity both in patients with established Crohn's disease and
those where Crohn's disease is suspected by virtue of its oral
presentation or where OFG is diagnosed by exclusion. A greater
liaison is required between medical and dental clinicians in
order to better define the diagnostic separation and multi-
disciplinary management of these patients.Statement of authorship
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